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Background: 14,15-Epoxyeicosatrienoic acids (14,15-EETs) generated from arachidonic acid by cytochrome P450
epoxygenases have beneficial effects in certain cardiovascular diseases, and increased 14,15-EET levels protect the
cardiovascular system. 14,15-EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding
14,15-dihydroxyeicosatrienoic acids (14,15-DHETs), which are generally less biologically active but more stable
metabolite. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an
increased risk of coronary heart disease (CHD), and the major CYP2J2 product is 14,15-EETs. 14,15-DHETs can be
considered a relevant marker of CYP2J2 activity. Therefore, the aim of the present study was to evaluate the plasma
14,15-DHET levels to reflect the 14,15-EET levels in an indirectly way in patients with CHD, and to highlight the
growing body of evidence that 14,15-EETs also play a role in anti-inflammatory and lipid-regulating effects in
patients with CHD. This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity
C-reactive protein (hs-CRP) and blood lipoproteins.
Methods: Samples of peripheral venous blood were drawn from 60 patients with CHD and 60 healthy controls. A
14,15-DHET enzyme-linked immunosorbent assay kit (14,15-DHET ELISA kit) was used to measure the plasma
14,15-DHET levels. Hs-CRP, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density
lipoprotein-cholesterol levels were measured.
Results: 14,15-DHET levels (2.53 ± 1.60 ng/mL) were significantly higher in patients with CHD as compared with
those of the healthy controls (1.65 ± 1.54 ng/mL, P < 0.05). There was a significant positive correlation between
14,15-DHETs and hs-CRP levels (R = 0.286, P = 0.027). However, there was no significant correlation between
14,15-DHETs and blood lipoproteins (all, P > 0.05).
Conclusions: Increased plasma 14,15-DHET levels reflect the decreased of 14,15-EET levels in an indirectly way.
Indicated that decreased plasma 14,15-EET levels might be involved in the inflammatory reaction process in
atherosclerosis.
Keywords: Coronary heart disease, Atherosclerosis, 14,15-epoxyeicosatrienoic acids, 14,15-dihydroxyeicosatrienoic
acids, Inflammation, LipoproteinsIntroduction
Over the past decade, it has become increasingly apparent
that epoxyeicosatrienoic acids (EETs) have cardiovascular
protective effects, including vasodilation, angiogenesis, de-
creasing platelet aggregation, and generally acting to main-
tain vascular homeostasis. More importantly, EETs have* Correspondence: xudanyan02@sina.com
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reproduction in any medium, provided the oranti-inflammatory effects that play an important role in
the prevention of coronary heart disease (CHD) [1-4].
EETs are hydrolyzed by soluble epoxide hydrolase (sEH)
to the corresponding dihydroxyeicosatrienoic acids
(DHETs); thus, it is expected that the inhibition of this
enzyme enhances the beneficial cardiovascular properties
of EETs [5]. Therefore, sEH inhibitors (sEHIs) have been
rapidly developed and have been proven beneficial in car-
diovascular diseases such as hypertension and CHD [5,6].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yang et al. Lipids in Health and Disease 2013, 12:151 Page 2 of 7
http://www.lipidworld.com/content/12/1/151It is well known that inflammation plays a very im-
portant role in the development and prognosis of CHD.
The initial findings of the anti-inflammatory properties
of EETs described by Node et al. [7] that EETs inhibited
the activation of nuclear factor kappa B (NF-κB), a key
transcription factor involved in the expression of numer-
ous pro-inflammatory genes. EETs were also found to in-
hibit the expression of vascular cell adhesion molecule-1
in human endothelial cells in response to tumor necrosis
factor-alpha, interleukin-1 alpha, or lipopolysaccharide
[7]. Some studies [8] have demonstrated that peroxisome
proliferator–activated receptor gamma (PPARγ) activa-
tion contributes to the anti-inflammatory effects of
cytochrome P450 (CYP)-derived EETs. A number of
studies [9-11] have also demonstrated that CYP-derived
EETs inhibit cyclooxygenase 2–mediated inflammatory
responses. Therefore, EETs might be an indicator re-
flecting the state of inflammation. But EETs are very un-
stable metabolites, it's rapidly hydrolyzed by sEH to the
less biologically active but more stable metabolites
DHETs. Spiecker et al. [12] demonstrated that a func-
tionally relevant polymorphism of the CYP2J2 gene is
independently associated with an increased risk of CHD,
and the major CYP2J2 product is 14,15-EETs. 14,15-
DHETs can be considered a relevant marker of CYP2J2
activity. Therefore, in our study we chosen 14,15-DHETs
to reflect the 14,15-EET levels in an indirectly way in
patients with CHD.
From another point of view, high-sensitivity C-reactive
protein (hs-CRP), an acute-phase reactive protein, is
now recognized as a good indicator of inflammation and
a pro-inflammatory atherogenic circulating marker that
has been proven an independent cardiac risk predictor
[13]. It has been shown that hs-CRP is of prognostic
value in patients with acute coronary syndromes and
plays an important role in the development of CHD
[14]. However, the relationship between EETs and
hs-CRP remains unclear.
Dyslipidemia also is an independent risk factor in the
progress of CHD [15,16]. Low-density lipoprotein
cholesterol (LDL-C) is atherogenic and represents a strong
cardiovascular risk factor [17]. High-density lipoprotein
cholesterol (HDL-C) mediates reverse cholesterol trans-
port and exerts several atheroprotective effects [18].
Epidemiologic evidence has shown that low HDL-C is a
strong and independent cardiovascular risk marker [19].
Some research has found that local adipose tissue inflam-
mation and inflammatory lipid mediators, including EETs,
may play important roles in regulating adipocyte function
and lipid metabolism [20] and EETs can activate PPARγ,
which may play important roles in lipid metabolism [21].
However, the specific mechanism is still unknown; hence,
we investigated the relationship between 14,15-DHETs and
blood lipoproteins to determine whether they are related.To date, there are no reports about the relationship
between 14,15-EETs and hs-CRP and blood lipoprotein
in patients with CHD. In order to explore the beneficial
effects of EETs further, we studied the plasma 14,15-
DHET levels in patients with CHD, and investigated the
relationship between 14,15-DHETs and hs-CRP as well
as blood lipoproteins in these patients.
Materials and methods
Subjects
We recruited 120 people for this study. We enrolled 60
CHD patients (44 men and 16 women) ranging in age
from 51 to 69 years old (average age 60.42 ± 8.75 years) in
the study, which spanned September 2010 to December
2012 in our hospital. We recruited 60 age- and sex-
matched healthy subjects as controls (42 men and 18
women, average age 61.09 ± 8.87 years).
The diagnosis of CHD was defined as having experi-
enced symptoms of myocardial ischemia such as angina,
and stenosis in at least one major epicardial coronary
artery by coronary angiography. All participants were
clinically stable and chest pain free at the time of their
study visit. Patients with the following diseases and situ-
ations were excluded from the CHD group: left ventricu-
lar systolic dysfunction (ejection fraction ≤ 35%), current
use of insulin, active autoimmune disease, history of
severe aortic stenosis, history of solid organ transplant
or dialysis, or history of cancer within the previous five
years. A detailed medical and medication history and
fasting serum chemistry and cholesterol panel were
obtained from the healthy volunteers; individuals with a
history of cardiovascular disease or risk factors for cor-
onary artery disease were excluded.
The Second Xiangya Hospital of Central South University
Ethics Committee approved the study protocol. Blood was
collected by venipuncture. Plasma was separated by centri-
fugation and stored at −80°C pending analysis.
Measurements and methods
We collected 120 samples of peripheral venous blood, and
then separated the plasma supernatant by centrifugation.
An enzyme-linked immunosorbent assay (ELISA) was
used to measure the plasma 14,15-DHET (14,15-DHET
ELISA kit; Detroit R&D Inc., Detroit, MI, USA) according
to the manual. A specialist who was unaware of the
subjects’ assignations analyzed the plasma hs-CRP, total
cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, and
biochemical indicators of liver and kidney function using a
Hitachi 7170A analyzer (Hitachi, Tokyo, Japan).
Statistical analysis
All data were analyzed with SPSS 16.0. Continuous vari-
ables between groups were analyzed by an independent
sample t-test. Correlations were tested by the Spearman
Table 1 Demographic and biochemical characteristics of
study participants
CHD patients Healthy controls P
n=60 n=60
Age (years) 60.42±8.75 61.09±8.87 NS
Male/Female 44/16 42/18 NS
BMI (kg/m2) 24.59±3.36 24.63±2.91 NS
Smoking cases (yes/no) 38/22 36/24 NS
TG (mmol/L) 1.75±0.91 1.33±0.68 0.041a
TC (mmol/L) 4.48±1.01 4.19±0.92 NS
HDL-C (mmol/L) 1.04±0.29 1.20±0.28 0.018a
LDL-C (mmol/L) 2.78±1.10 2.24±0.71 0.036a
FBS (mmol/L) 6.49±3.06 5.94±2.79 NS
BUN (mmol/L) 5.51±1.80 5.67±1.40 NS
Cr (umol/L) 81.61±19.33 78.85±16.87 NS
ALT (mmol/L) 24.68±9.99 20.58±8.21 NS
AST (mmol/L) 26.79±9.45 24.24±7.44 NS
ACE inhibitor or
ARB (%)
36 (60%) 0 (0%)
Beta-blocker (%) 49 (82%) 0 (0%)
Statin (%) 60 (100%) 0 (0%)
Aspirin (%) 60 (100%) 0 (0%)
Clopidogrel (%) 15 (25%) 0 (0%)
aP < 0.05; CHD: Coronary heart disease; BMI: body mass index; TG: triglyceride;
TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C:
low-density lipoprotein cholesterol; FBS: fasting blood glucose; BUN: blood
urea nitrogen; Cr: serum creatinine; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; NS: not significant.
Table 2 14,15-DHETs and hs-CRP levels between the two
groups
CHD patients Healthy controls P
n = 60 n = 60
14,15-DHETS (ng/ml) 2.53 ±1.60 1.65 ±1.54 0.036a
hs-CRP (mg/L) 2.92±1.20 1.89±1.09 0.001b
aP < 0.05; bP < 0.01; 14,15-DHETs: 14,15-dihydroxyeicosatrienoic acids; hs-CRP:
high-sensitivity C-reactive protein.
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significant if the null hypothesis could be rejected with
>95% confidence. P-values < 0.05 (two-tailed) were consid-
ered to indicate statistical significance. The log-transformed
hs-CRP and other values are presented as mean ± standard
error (mean ± SE).
Results
Characteristics of study participants
TG and LDL-C levels were higher in the CHD patients
than in the control group (P < 0.05), but the HDL-C
levels of the CHD patients tended to be lower (P < 0.05).
No significant difference was observed for other indica-
tors such as age, sex, body mass index, smoking status,
TC, fasting blood glucose, blood urea nitrogen, serum
creatinine, alanine aminotransferase, and aspartate ami-
notransferase (all, P > 0.05; Table 1).
14,15-DHETs and hs-CRP levels between the two groups
As shown in Table 2, the 14,15-DHET levels in the CHD
group were significantly higher than that in the control
group (P < 0.05; Table 2; Figure 1), while hs-CRP levels
were significantly higher in the CHD group (P < 0.01;
Table 2; Figure 2).
Correlation analysis of 14,15-DHETs and hs-CRP and
blood lipoproteins
We performed correlation analysis to elucidate the re-
lationship between 14,15-DHETs and hs-CRP and blood
lipoproteins. There was a significant positive correlation
between 14,15-DHET and hs-CRP levels (R = 0.286, P =
0.027). However, there did not appear to be a significant
correlation between 14,15-DHETs and blood lipopro-
teins such as TC, TG, LDL-C, and HDL-C (P > 0.05;
Table 3; Figure 3).
Discussion
In the present study, we found higher serum 14,15-DHETs,
hs-CRP, TG, and LDL-C concentrations in patients with
CHD as compared to the control group, but HDL-C levels
were lower in patients with CHD. There was also a signifi-
cant positive correlation between 14,15-DHETand hs-CRP
levels. However, there was no specific relationship between
14,15-DHETs and blood lipoproteins.
The results of the present study show that the
14,15-DHET levels were significantly higher in patients
with CHD. The process of CHD is closely related with
coronary endothelial injury and dysfunction, and myocar-
dial ischemia. Endothelial cells play important roles in vas-
culogenesis and re-endothelialization after ischemic injury.
One of the functions of EET that has been explored is the
ability of EETs to prevent apoptosis and promote the
growth of endothelial cells [22-24]. A potent inhibitor of
apoptosis, 14,15-EETs can serve as an intracellular secondmessenger for epidermal growth factor in cells expressing
epoxygenase activity, and promote endothelial cell growth
[23]. Yan et al. [25] found that specific epoxidation of EET
sites produces endogenous PPARγ agonists, increasing cell
proliferators, which might affect angiogenesis and cardiac
recovery after ischemic infarct and reperfusion. Xu et al.
[26] also demonstrated that sEHIs can promote angiogen-
esis by activating the EET–PPARγ pathway, which in turn
increases vascular endothelial growth factor and hypoxia-
inducible factor 1 alpha and triggers the migration and
proliferation of endothelial progenitor cells. Numerous
studies have suggested the beneficial effects of EETs on
cardiac recovery following ischemia/reperfusion (I/R).
Figure 1 14,15-DHET levels between the two groups. CHD:
Coronary heart disease; 14,15-DHETs: 14,15-dihydroxyeicosatrienoic
acids.
Table 3 Related coefficients of 14,15-DHETs and hs-CRP,
TG, TC, LDL-C, and HDL-C in patients with CHD
hs-CRP TG TC LDL-C HDL-C
14,15-DHETs 0.286 0.053 0.134 0.058 −0.005
(P=0.027)a (P=0.638) (P=0.304) (P=0.652) (P=0.968)
aP < 0.05; 14,15-DHETs: 14,15-dihydroxyeicosatrienoic acids; hs-CRP: high-
sensitivity C-reactive protein; TG: triglyceride; TC: total cholesterol; LDL-C: low-
density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol.
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duced a marked reduction in infarct size in dogs. Another
study reported that the expression of CYP2J2 in car-
diomyocytes led to improved functional recovery and
reduced infarct size after ischemia [28]. EETs were reported
to have aided in the preservation of mitochondrial integrity
and membrane potential during I/R [29]. Similarly, EETs
have been shown to release met-enkephalin, which binds
δ-opioid receptors to reduce infarct size after I/R in rat
heart [30]. EETs exert many other cardioprotective effects,
including the reduction of myocardial stunning, myocardial
infarct size, and inflammatory response; prevention of the
onset of left ventricular hypertrophy and subsequent re-
modeling, which leads to heart failure; and reduction of the
incidence of cardiac arrhythmias associated with heart fail-
ure [31]. Our findings are consistent with these results. But
in Theken’s [32] study, CHD patients had higher EETs and
tended to have lower DHETs compared to healthy volun-
teers, and significantly lower apparent sEH metabolic activ-
ity in the presence of stable atherosclerotic cardiovascular
disease. These results are differ from us, we can not rule
out the possibility that the detected difference will achieveFigure 2 Hs-CRP levels between the two groups. CHD: Coronary
heart disease; hs-CRP: high-sensitivity C-reactive protein.statistical significance when future investigations study
much larger patient groups. Even so, all the results lead up
to the conclusion that EETs have a positive effect on the
cardiovascular system.
We found that the plasma hs-CRP levels in patients
with CHD were significantly higher than that in the con-
trol group. Inflammation is an important feature of ath-
erosclerotic plaque [33,34]. As a vascular inflammatory
marker, hs-CRP is closely related to cardiovascular dis-
ease. In patients with CHD, serum CRP levels gradually
increase with the progress of the disease [35]. This is
partially because CHD can cause ischemia and hypoxia,
which leads to local tissue damage, myocardial infarc-
tion, myocardial fibrosis and necrosis, and neutrophil
infiltration, thus stimulating the production of CRP. This
clearly suggests that serum CRP levels are associated
with the occurrence and development of CHD [35].
Schnell-Inderst et al. [13] found that the incidence of
cardiovascular events was closely related to hs-CRP
levels, and that hs-CRP can be used as an additional
predictor in cardiovascular events.
We found a significant positive correlation between
14,15-DHET and hs-CRP levels in patients with CHD.
This conclusion reflected that there might be a negative
correlation between 14,15-EETs and hs-CRP in patientsFigure 3 Scatter plot of the correlations between 14,15-DHETs
and hs-CRP in patients with CHD. 14,15-DHETs: 14,15-
dihydroxyeicosatrienoic acids. hs-CRP: high-sensitivity C-reactive
protein. The scatter diagram depicts the 14,15-DHETs and hs-CRP
concentrations. Spearman correlation analysis revealed a positive
correlation between serum 14,15-DHETs and hs-CRP.
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cytokine-induced endothelial cell adhesion molecule ex-
pression and prevented leukocyte adhesion to the vascu-
lar wall by a mechanism involving the inhibition of the
transcription factors NF-κB and inhibitor of kappa B
kinase. The inhibitory effects of EETs were independent
of their membrane-hyperpolarizing effects, suggesting
that these molecules play an important nonvasodilatory
role in vascular inflammation [36]. These findings and
our results strongly suggest that EETs may be involved
in the anti-atherosclerotic process by their inhibition of
the inflammatory response. But in Schuck’s [37] re-
search, no associations were observed between bio-
markers of CYP-mediated eicosanoid metabolism and
hs-CRP, it suggest that CYP-derived eicosanoids may be
important in the regulation of vascular, but not hepatic
or systemic, inflammation in humans. These results are
differ from us, we can not rule out the possibility that
the detected difference will achieve statistical signifi-
cance, or the medication used causes different results.
We found much evidence from epidemiologic, clinical,
and laboratory data indicating that elevated TG levels
are an independent risk factor for cardiovascular disease
[38,39]. However, we found no significant correlation be-
tween 14,15-DHETs and TC, TG, LDL-C, and HDL-C. It
is worth mentioning that some studies have demon-
strated that sEHIs have anti-atherosclerotic effects, and
that the anti-atherosclerotic effects are correlated with
elevation in EET levels and associated with LDL-C re-
duction and HDL-C elevation, as well as attenuation of
the expression of pro-inflammatory genes and proteins
[40-42]. Zhang et al. [40] demonstrated that sEH inhib-
ition could lower circulating cholesterol levels, which
could also contribute to the attenuation of atherosclerosis.
In contrast, many studies have demonstrated that
lipoproteins play a key role in precipitating CHD [43].
Moreover, some studies have suggested that in view of its
molecular structures, sEH is involved in cholesterol, fatty
acid, and lipid metabolism [44-46]. It is known that EETs
are potent endogenous PPARα agonists, and as PPARα
activation can increase HDL-C by increasing the concen-
tration of apolipoproteins A-I and A-II and by stimulating
the reverse cholesterol transport pathway [47] it is expected
to affect blood lipoproteins. However, we did not find a
significant correlation between 14,15-DHETs and blood
lipoproteins. Pritchard et al. [48] found that endothelial cells
incubated in atherogenic LDL concentrations produced
substantially greater quantities of EET species. Karara et al.
[49] also found that the lipoprotein fraction with the
highest EET concentration was LDL, followed by HDL and
very low–density lipoprotein cholesterol. Thus far, no
evidence shows that EETs and blood lipoproteins are
not correlated. Therefore, we cannot rule out the possibil-
ity that the detected difference will achieve statisticalsignificance when future investigations study much larger
patient groups.
This study tested the relationship between 14,15-DHETs
and hs-CRP and blood lipoproteins in patients with CHD.
The in vivo cross-sectional design of the study presents
several limitations. First, the levels of sEH and its enzym-
atic activity could be different between groups, 14,15-EET,
14,15-DHET, leukotoxin, and leukotoxin diol are potential
biomarkers for assessing sEH activity in clinical trial sub-
jects, our further studies are necessary to enroll these indi-
cators to figure out the differences between two groups. It
must also be noted that the we did not separated smoker
and non-smoker, but there were no significant difference
in the number of smokers between two groups, so the
measured results are comparable. In addition, our analysis
compared a well-treated population of patients with ad-
vanced cardiovascular disease to healthy individuals with
no risk factors for cardiovascular disease. Thus, multiple
potential confounding factors may have influenced the dif-
ferences in 14,15-DHETs, hs-CRP and blood lipoprotein.
We cannot determine whether the observed differences
are due to the presence of atherosclerotic disease, or a
consequence of drug therapy. Since the effects of these
established therapies on circulating CYP-derived eicosa-
noid levels, and specifically sEH expression and metabolic
activity, in humans are unknown, further studies are ne-
cessary to quantify these effects. And the number of pa-
tients enrolled in the study was relatively small, which
might cause bias. Therefore, to expand the samples is what
we need to do in our further researches.Conclusion
In summary, the plasma 14,15-DHET levels in patients
with CHD were significantly higher and were positive
correlated with hs-CRP levels, suggesting that the de-
crease in 14,15-EET levels may be involved in the in-
flammatory reaction process in atherosclerosis. The
correlation of 14,15-EETs and blood lipoproteins re-
mains to be investigated.Consent
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